BCI on the Road

BCI away from Charterhouse Square

BCI scientist visits politicians in Westminster

Posted in General News, BCI on the Road Published by Administrator 20 February 2019

The Royal Society Pairing Scheme

BCI scientist visits politicians in Westminster

Dr John Riches from our Centre for Haemato-Oncology swapped a lab coat for legislation when he visited Zoë Grunewald (Second Clerk - Commons Science and Technology Committee) at the House of Commons for a week in Westminster. The week (26-30th November 2018) was part of a unique pairing scheme run by the Royal Society.

BCI at the 60th ASH Annual Meeting

Posted in General News, BCI on the Road Published by Bethan Warman 14 January 2019

‘The premier event in malignant and non-malignant haematology’

BCI at the 60th ASH Annual Meeting

Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego on 1st-4th December 2018. The ASH Annual Meeting provides an invaluable opportunity to showcase the work being conducted here at the BCI and brings together professionals from all subspecialties of blood disease research.

Globalisation of technology-enhanced learning for surgical education

Posted in General News, BCI on the Road Published by Bethan Warman 11 January 2019

Globalisation of technology-enhanced learning for surgical education

Mr Patel is a leading expert in developing higher education degrees for acquiring surgical skills by simulation. Mr Patel and his colleague, Professor Shafi Ahmed were invited to Bolivia to visit Universidad de Aquino Bolivia to discuss the use of technology-enhanced learning for surgical education as preparations were made for the launch of Bolivia’s first digital hospital.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.